Interferon-free sofosbuvir-based anti-HCV therapy after liver transplantation

Annals of Transplantation

Volumn 20, Issue , 2015, Pages 561-568

  Seifert, Leon Louis ^a   Vorona, Elena ^a   Bester, Caroline ^a   Stahl, Martin ^a   Hüsing, Anna ^a   Beckebaum, Susanne ^a   Kabar, Iyad ^a   Heinzow, Hauke ^a   Schmidt, Hartmut H J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Elasticity imaging techniques; Hepatitis C; Liver transplantation

Indexed keywords

FILGRASTIM; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SAFETY; FEMALE; GRAFT INFECTION; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; GRAFT SURVIVAL; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84942804024     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.893640     Document Type: Article

References (57)

1. World Health Organisation: Hepatitis C: global prevalence (update). Wkly Epidemiol Rec, 2000; 75: 18-19
2. Marcellin P: Hepatitis C: the clinical spectrum of the disease. J Hepatol, 1999; 31: 9-16
3. Zoulim F, Chevallier M, Maynard M, Trepo C: Clinical consequences of hepatitis C virus infection. Rev Med Virol, 2003; 13: 57-68
4. Kim W, Terraul N, Pedersen R et al: Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology, 2009; 137: 1680-86
5. Swain MG, Lai M-Y, Shiffman ML et al: A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology, 2010; 139: 1593-601
6. Ueno Y, Sollano J, Farrell G: Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol, 2009; 24: 531-36
7. Berenguer M, Lopez-Labrador FX, Wright TL: Hepatitis C and liver transplantation. J Hepatol, 2001; 35: 666-78
8. Wiesner RH, Sorrell M, Villamil F: Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl, 2003; 9: 1-9
9. Garcia-Retortillo M, Forns X, Feliu A et al: Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology, 2002; 35: 680-87
10. Wawrzynowicz-Syczewska M, Zeair S, Andruszkiewicz A et al: Impact of antiviral treatment on survival in HCV-positive liver recipients. Ann Transplant, 2014; 19: 367-72
11. Picciotto FP, Tritto G, Lanza AG et al: Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol, 2007; 46: 459-65
12. Jacobson IM, Gordon SC, Kowdley KV et al: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. NEngl J Med, 2013; 368: 1867-77
13. Lawitz E, Mangia A, Wyles D et al: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med, 2013; 368(20): 1878-87
14. Degasperi E, Aghemo A: Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med, 2014; 6: 25-33
15. Hofmann WP, Sarrazin C, Zeuzem S: Current standards in the treatment of chronic Hepatitis C. Dtsch Arztebl Int, 2012; 109: 352-58
16. Gara N, Ghany MG: What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis, 2013; 56: 1629-36
17. Lawitz E, Mangia A, Wyles D et al: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med, 2013; 368: 1878-87
18. Llado L, Fabregat J, Castellote J et al: Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: Results of a prospective randomized study. Liver Transpl, 2008; 14: 1752-60
19. Socha Ł, Karpińska E, Jurczyk K et al: Rescue therapy with intravenous silibinin in liver transplant recipients with recurrent HCV hepatitis-two case reports. Ann Transplant, 2014; 19: 161-64
20. Kim B, Trivedi A, Thung SN, Grewak P: Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Semin Liver Dis, 2014; 34: 108-12
21. Curry MP, Forns X, Chung RT et al: Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study. Gastroenterology, 2014; 148(1): 100-7
22. Delabaudiere C, Lavayssiere L, Dorr G et al: Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. Transpl Int, 2015; 28(2): 255-58
23. Borentain P, Colson P, Dhiver C et al: Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient. Antivir Ther, 2014 [Epub ahead of print]
24. Gane EJ, Stedman CA, Hyland RH et al: Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med, 2013; 368: 34-44
25. Fried MW, Shiffman ML, Reddy KR et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 2002; 347: 975-82
26. Manns MP, McHutchison JG, Gordon SC et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001; 358: 958-65
27. Sarrazin C, Berg T, Cornberg M et al: Expert opinion on boceprevir-and telaprevir-based triple therapies of chronic hepatitis C. Z Gastroenterol, 2012; 50: 57-72
28. Hezode C, Fontaine H, Dorival C et al: CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterol, 2014; 147: 132-42
29. Neumann U, Puhl G, Bahra M et al: Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation, 2006; 82: 43-47
30. Beckebaum S, Cicinnati VR, Zhang X et al: Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: Preliminary results of an open prospective study. Transplant Proc, 2004; 36: 1489-91
31. Biselli M, Andreone P, Gramenzi A et al: Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in naıve and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis, 2006; 38: 27-32
32. Castedal M, Felldin M, Backman L et al: Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis. Transplant Proc, 2005; 37: 3313-14
33. Chalasani N, Manzarbeitia C, Ferenci P et al: Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology, 2005; 41: 289-98
34. Dumortier J, Scoazec JY, Chevallier P et al: Treatment of recurrent hepatitis C after liver transplantation: A pilot study of 2068. Dig Dis Sci, 2010; 55: 2063-69
35. Fontana M, Ciuffreda D, Moradpour D et al: Combined antiviral therapy for recurrent hepatitis C virus after liver transplantation. Transplantation, 2007; 83: 525-26
36. Heydtmann M, Freshwater D, Dudley T et al: Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant, 2006; 6: 825-33
37. Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E et al: Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc, 2005; 37: 2207-8
38. Mukherjee S, Rogge J, Weaver L et al: Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc, 2003; 35: 3042-44
39. Akamatsu N, Sugawara Y: Liver transplantation and hepatitis C. Int J Hepatol, 2012; 2012: 686135
40. Kanizaj TF, Colić-Cvrlje V, Mrzljak A, Ostojić R: Treatment of recurrent HCV infection after liver transplantation. Acta Med Croatica, 2013; 67: 373-81
41. Werner CR, Egetemeyr DP, Nadalin S et al: Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: Single center experience with telaprevir-based triple therapy. Z Gastroenterol, 2014; 52: 27-34
42. Roche B, Sebagh M, Canfora ML et al: Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl, 2008; 14: 1766-77
43. Abe H, Tsubota A, Shimada N et al: Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype. Hepatol Res, 2015; 45(4): 387-96
44. US Food and Drug Administration. Available at: http: //www. accessdata. fda. gov/drugsatfda_docs/label/2011/202258lbl. pdf. Accessed 20 May 2014
45. US Food and Drug Administration. Available at: http: //www. accessdata. fda. gov/drugsatfda_docs/label/2011/201917lbl. pdf. Accessed 20 May 2014
46. De Franceschi L, Fattovich G, Turrini F et al: Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology, 2000; 31: 997-1004
47. Hadziyannis SJ, Sette H Jr, Morgan TR et al: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med, 2004; 140: 346-55
48. Manns MP, McHutchison JG, Gordon SC et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001; 358: 958-65
49. Jacobson IM, McHutchison JG, Dusheiko G et al: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med, 2011; 364: 2405-16
50. Poordad F, McCone J Jr, Bacon BR et al: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med, 2011; 364: 1195-206
51. Berenguer M: Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol, 2008; 49: 274-87
52. Sharma P, Dhawan S, Bansal R et al: The usefulness of transient elastography by FibroScan for the evaluation of liver fibrosis. Indian J Gastroenterol, 2014; 33: 445-51
53. Castera L, Vergniol J, Foucher J et al: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 2005; 128: 343-50
54. De Ledinghen V, Vergniol J: Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices, 2010; 7: 811-23
55. Smith JO, Sterling RK: Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther, 2009; 30: 557-76
56. Mahajan S, Avasthi A, Grover S, Chawla YK: Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection. J Psychosom Res, 2014; 77: 109-15
57. Raison CL, Borisov AS, Broadwell SD et al: Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry, 2005; 66: 41-48